949904-53-4

Basic information

• Product Name: 3-((1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl)benzaMide hydrochloride
• Synonyms: 3-((1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl)benzaMide hydrochloride
• CAS NO: 949904-53-4
• Molecular Formula: C₁₄H₁₈N₂O*ClH
• Molecular Weight: 266.76646
• Mol File: 949904-53-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-((1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl)benzaMide hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-((1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl)benzaMide hydrochloride(949904-53-4)
• EPA Substance Registry System: 3-((1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl)benzaMide hydrochloride(949904-53-4)

Safety Data

• Hazardous Substances Data: 949904-53-4(Hazardous Substances Data)

Usage

General Description

3-((1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl)benzaMide hydrochloride is a chemical compound that belongs to the class of benzamide derivatives. It is a hydrochloride salt of the benzamide derivative with a structure containing an 8-azabicyclo[3.2.1]octane ring system. 3-((1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl)benzaMide hydrochloride has potential pharmaceutical applications due to its interaction with the central nervous system as a potential modulator of neurotransmitter systems. Its structural features and pharmacological properties make it a potential candidate for the development of new drugs for the treatment of various neurological and psychiatric disorders. Further research and clinical studies are needed to fully elucidate its therapeutic potential.

Upstream product

• 351422-73-6 (3-(aminocarbonyl)phenyl)boronic acid 
• 949902-11-8 3-endo-(8-azabicyclo[3.2.1]oct-3-yl)-benzamide 
• 949903-29-1 3-endo-[8-(2,2,2-trifluoroacetyl)-8-azabicyclo[3.2.1]oct-3-yl]-benzonitrile 

Downstream Products

• 1122649-19-7 3-endo-[8-(1-benzyl-1H-imidazol-4-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]benzamide 
• 1125453-75-9 {4-[3-endo-(3-carbamoylphenyl)-8-aza-bicyclo[3.2.1]oct-8-yl]butyl}-(2-ethylbutyl)-carbamic acid tert-butyl ester 
• 949902-36-7 3-endo-{8-[2-(cyclohexylmethylamino)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}benzamide 
• 1125454-28-5 C₂₄H₃₇N₃O₃ 
• 1125454-29-6 C₂₆H₄₁N₃O₃ 
• 1125454-30-9 C₂₇H₄₃N₃O₃ 
• 1125454-31-0 C₂₈H₄₅N₃O₃ 

Relevant articles and documents

Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist

The effects of opioids in the central nervous system (CNS) provide significant benefit in the treatment of pain but can also lead to physical dependence and addiction, which has contributed to a growing opioid epidemic in the United States. Gastrointestinal dysfunction is an additional serious consequence of opioid use, and this can be treated with a localized drug distribution of a non-CNS penetrant, peripherally restricted opioid receptor antagonist. Herein, we describe the application of Theravance's multivalent approach to drug discovery coupled with a physicochemical property design strategy by which the N-substituted-endo-3-(8-aza-bicyclo[3.2.1]oct-3-yl)-phenyl carboxamide series of μ-opioid receptor antagonists was optimized to afford the orally absorbed, non-CNS penetrant, Phase 3 ready clinical compound axelopran (TD-1211) 19i as a potential treatment for opioid-induced constipation.

Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, and a are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opi